New Review Examines GIP Signaling Tied to Retatrutide, Published Oct 2026

A new publication dated October 22, 2026 presents a narrative review relevant to retatrutide research. The paper, titled "Glucose-dependent insulinotropic polypeptide (GIP) signaling in visceral and subcutaneous adipose tissue: implications for obesity and metabolic disease-a narrative review with a structured literature search," appears in the journal Reviews in Endocrine & Metabolic Disorders. The review uses a structured literature search approach to examine GIP signaling across visceral and subcutaneous adipose tissue types. It addresses implications for obesity and metabolic disease as described in the title. This entry reflects the publication record only, including its title, journal, and date of release. No specific findings, data, or conclusions from the review are detailed here. Readers interested in the full scope of the analysis should consult the original source directly. Retatrutide is currently classified as an approved compound according to available regulatory status information. For broader context on retatrutide, including its mechanism and background, readers can refer to the compound overview.